Prnewswire·2025-11-06 00:17Core Viewpoint - Metsera, Inc. has successfully defended against Pfizer's request for a temporary restraining order, allowing its Board of Directors to act in the best interests of shareholders [1][2]. Company Response to Litigation - Metsera expresses satisfaction with the Delaware Court of Chancery's ruling, which denies Pfizer's request to restrict the company's Board actions [1]. - The company asserts that Pfizer's litigation arguments are unfounded and emphasizes its commitment to shareholders and patients [2]. Acquisition Context - Pfizer has reiterated its intention to continue litigation against Metsera, which is related to Pfizer's proposed acquisition of the company [2]. - The ongoing litigation may impact the acquisition process, including potential costs and regulatory approvals [5]. Regulatory and Market Considerations - Metsera has filed necessary documents with the SEC regarding the proposed acquisition, including proxy statements for stockholders [5]. - Investors are encouraged to review these documents for important information related to the transaction [5]. Additional Information - Metsera's Board of Directors is actively engaged in evaluating competing offers, including one from Novo Nordisk, which has been deemed "superior" [9].